ISOPP CAPhO 2025 Symposium: Sponsored Lunch Symposium Johnson and Johnson - Latest Learnings and Best Practices for the Implementation of Bispecific Antibodies for Multiple Myeloma in the Community
Details
This symposium will enable Canadian pharmacists involved in the management of relapsed/refractory Multiple Myeloma (RRMM) to determine the optimal patient selection and management strategies for triple class-exposed patients receiving bispecific antibodies, with a focus on administration in the Community setting.
Learning Objectives:
- Explore patient selection for bispecific antibodies for the management of relapsed/refractory Multiple Myeloma (RRMM) in Canada
- Share best practices for the optimal management of adverse events associated with bispecific antibodies for Multiple Myeloma
- Consider the role of the pharmacist to support patient management and the delivery of bispecific antibodies for Multiple Myeloma within the Community setting